[Estimation of eosinophilia, immunoglobulin E and eosinophilic cationic protein concentration during the treatment of toxocariasis].

Toxocara canis and Toxocara cati do not transform in human organism into a mature form and they circulate reaching various organs and tissues causing characteristic symptoms. Activated eosinophils, which play a significant role in parasitic invasion, contain in their granules eosinophilic cationic protein (ECP) of strong pro-inflammatory activity. The aim of the study was to estimate the concentration of immunoglobulin E, peripheral blood eosinophilia and serum concentration of eosinophilic cationic protein in children treated for toxocariasis and the analysis of their value as the markers of active invasion and the therapy efficacy. The study included 45 children, aged from 3 to 18 years with Toxocara canis infection diagnosed for the first time. The children were diagnosed and treated at the Department of Gastroenterology, in the Outpatient Gastrointestinal and Allergologic Clinic, Institute Polish Mother Health Centre. T. canis larva infection was diagnosed based on serological investigation using immunoenzymatic ELISA test (Bordier Affinity Products, Switzerland). The tests (percentage of eosinophilia in peripheral blood, ECP, IgE) were performed after diagnosis and every 3 months since the beginning of the therapy. In children with toxocariasis its covert form was diagnosed and mebendazole was administered. Among the children with toxocariasis eosinophilia was found in 14 (31.1%) before therapy. Mean percentage of peripheral blood eosinophils was 5.58% in children with toxocariasis. The concentration of IgE was elevated in these children and was significantly higher than in the control group (p=0.002). Mean IgE concentration after 3-and 6-month therapy decreased IgE(I) vs IgE(III) (p=0.01), but it was still higher than normal value. In children with toxocariasis the ECP concentration was 30.19 microg/l before the therapy and was significantly higher than in the control group (p<0.05); after 6 months of the therapy it decreased significantly (p<0.05). Eosinophilic cationic protein and eosinophilia can be the markers of Toxocara canis infection activity. The determination of immunoglobulin E and eosinophilic cationic protein concentration may be useful for toxocariasis therapy monitoring.

[1]  R. Fabre,et al.  Eosinophil cationic protein, specific IgE and IgG4 in human toxocariasis. , 2006, Journal of helminthology.

[2]  Myungshin Kim,et al.  Plasma eosinophil cationic protein, interleukin-5, and ECP/Eo count ratio in patients with various eosinophilic diseases. , 2006, Annals of clinical and laboratory science.

[3]  D. Despommier,et al.  Toxocariasis: Clinical Aspects, Epidemiology, Medical Ecology, and Molecular Aspects , 2003, Clinical Microbiology Reviews.

[4]  Z. Pawłowski.  Toxocariasis in humans: clinical expression and treatment dilemma , 2001, Journal of Helminthology.

[5]  R. Fabre,et al.  Eosinophil cationic protein as a possible marker of active human Toxocara infection , 2001, Allergy.

[6]  N. Brattig,et al.  Eosinophils, eosinophil cationic protein and eosinophil-derived neurotoxin in serum and urine of patients with onchocerciasis coinfected with intestinal nematodes and in urinary schistosomiasis. , 1999, Acta tropica.

[7]  G. Cain,et al.  Identification, characterization and expression of Toxocara canis nematode polyprotein allergen TBA‐1 , 1998, Parasite immunology.

[8]  P. Venge,et al.  MOLECULES IN FOCUS. EOSINOPHIL CATIONIC PROTEIN (ECP) , 1998 .

[9]  Iguchi,et al.  Clinical utility of serum levels of eosinophil cationic protein (ECP) for monitoring and predicting clinical course in childhood asthma , 1998, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[10]  J. Byström,et al.  Eosinophil cationic protein (ECP). , 1998, The international journal of biochemistry & cell biology.

[11]  T. Fukuda,et al.  Serum levels of eosinophil cationic protein and IL-5 in patients with asthma without systemic corticosteroids. , 1997, International Archives of Allergy and Immunology.

[12]  J. Magnaval.  Comparative efficacy of diethylcarbamazine and mebendazole for the treatment of human toxocariasis , 1995, Parasitology.

[13]  F. Nijkamp,et al.  Toxocara canis‐induced murine pulmonary inflammation: analysis of cells and proteins in lung tissue and bronchoalveolar lavage fluid , 1994, Parasite immunology.

[14]  M. Chapman,et al.  Asthma in Tanta, Egypt: serologic analysis of total and specific IgE antibody levels and their relationship to parasite infection. , 1991, International archives of allergy and applied immunology.

[15]  L. Glickman,et al.  Asymptomatic Toxocariasis in Children , 1987, Clinical pediatrics.

[16]  R. Maizels,et al.  Shared carbohydrate epitopes on distinct surface and secreted antigens of the parasitic nematode Toxocara canis. , 1987, Journal of immunology.

[17]  H. Smith,et al.  The production of human A and B blood group like substances by in vitro maintained second stage Toxocara canis larvae: their presence on the outer larval surfaces and in their excretions/secretions. , 1983, Clinical and experimental immunology.

[18]  K. Turner,et al.  Non-specific potentiation of IgE by parasitic infections in man. , 1979, International archives of allergy and applied immunology.

[19]  H. Cole,et al.  Larva migrans. , 1947, Archives of dermatology and syphilology.